文献速递治疗药物监测与药物基因组学药物相互作用药物不良反应与药物警戒

口服TKI与PARP抑制剂治疗药物监测及模型引导精准给药的临床实施框架

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation.
PubMed 文献 · Clin Pharmacokinet · 2026-06-12

本文为问题导向叙述性综述,评估口服酪氨酸激酶抑制剂和PARP抑制剂治疗药物监测与模型引导精准给药的临床适用性。伊马替尼和舒尼替尼有高级别证据支持暴露引导给药,部分药物支持选择性实施,部分仅在毒性驱动场景监测。稳态谷浓度是默认采样策略,模型引导精准给药可整合协变量模拟个体化方案。

要点

  • 伊马替尼和舒尼替尼有前瞻性干预证据支持暴露引导给药以改善结局。
  • 阿来替尼、卡博替尼、曲美替尼和仑伐替尼支持选择性实施监测。
  • 奥希替尼、布格替尼、奥拉帕利和尼拉帕利监测更适用于毒性驱动场景。

核心结论

  • 治疗药物监测和模型引导精准给药已可在部分口服靶向药物中选择性临床采用。
  • 未来需前瞻性试验整合药物计量学工具与以患者为中心的结局以完善暴露靶标。

研究设计与样本

  • 本文为问题导向叙述性综述,评估口服靶向药物治疗药物监测与模型引导精准给药的临床适用性。
  • 评估药物包括EGFR、ALK、BCR-ABL、VEGFR、MEK和多激酶抑制剂及PARP抑制剂。
  • 对每种药物评估暴露-效应或暴露-毒性关系、验证 assay 可用性和可操作浓度阈值。
  • 整合更新的治疗药物监测有用性评分以反映推荐强度。

主要发现

  • 伊马替尼和舒尼替尼有高级别证据(含前瞻性干预研究)支持暴露引导给药改善分子或临床结局。
  • 阿来替尼、卡博替尼、曲美替尼和仑伐替尼存在一致的暴露-效应或暴露-毒性关系及实用浓度阈值。
  • 奥希替尼、布格替尼、奥拉帕利和尼拉帕利监测在毒性驱动场景最具临床相关性。
  • 劳拉替尼目前缺乏明确治疗窗,限制常规应用。
  • 稳态谷浓度是各药物默认采样策略。

关键数值与推荐

  • 伊马替尼和舒尼替尼达到预设谷浓度靶标时显示改善的分子或临床结局。
  • 阿来替尼、卡博替尼、曲美替尼和仑伐替尼有实用浓度阈值支持选择性实施,但随机验证有限。
  • 劳拉替尼缺乏明确治疗窗,限制常规适用性。

临床怎么用

  • 临床场景需测量药物浓度:早期或意外疾病进展、反复或严重不良事件、疑似药物相互作用、吸收改变、器官功能障碍或依从性担忧。
  • 模型引导精准给药整合患者特异性协变量与药代动力学模型以模拟个体化给药方案。
  • 稳态谷浓度为默认采样策略。

局限性

  • 部分药物仅基于观察性暴露-效应关系,随机验证有限。
  • 劳拉替尼缺乏明确治疗窗限制常规应用。
  • 需未来前瞻性试验完善暴露靶标并扩展循证实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oral tyrosine kinase inhibitors and poly (adenosine diphosphate-ribose) polymerase inhibitors are widely used across solid tumors and hematologic malignancies and are typically administered at fixed doses. However, substantial interindividual pharmacokinetic variability results in heterogeneous systemic exposure, potentially leading to underexposure with reduced antitumor efficacy or overexposure with preventable toxicity. Therapeutic drug monitoring and model-informed precision dosing have emerged as complementary strategies to individualize dosing and optimize the exposure-response balance in routine oncology practice. This narrative problem-oriented review evaluates the clinical applicability of therapeutic drug monitoring and model-informed precision dosing for selected oral targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor, mitogen-activated protein kinase kinase, and multi-kinase inhibitors, as well as poly(adenosine diphosphate-ribose) polymerase inhibitors. For each agent, we assessed the presence of clinically meaningful exposure-response or exposure-toxicity relationships, the availability of validated assays, and the existence of actionable concentration thresholds. We also integrated an updated therapeutic drug monitoring usefulness score to contextualize the strength of recommendation. High-level evidence, including prospective interventional studies, supports exposure-guided dosing for imatinib and sunitinib, demonstrating improved molecular or clinical outcomes when predefined trough concentration targets are achieved. For alectinib, cabozantinib, trametinib, and lenvatinib, consistent exposure-response or exposure-toxicity relationships and pragmatic concentration thresholds support selective implementation, although randomized validation remains limited. For agents such as osimertinib, brigatinib, olaparib, and niraparib, monitoring appears most clinically relevant in toxicity-driven scenarios rather than for efficacy optimization. In contrast, lorlatinib currently lacks a clearly defined therapeutic window, limiting routine applicability. Across drugs, steady-state trough concentration remains the default sampling strategy. Clinical scenarios warranting measurement include early or unexpected disease progression, recurrent or severe adverse events, suspected drug-drug interactions, altered absorption, organ dysfunction, or concerns regarding adherence. Model-informed precision dosing extends conventional monitoring by integrating patient-specific covariates with pharmacokinetic models to simulate individualized dosing regimens. In conclusion, therapeutic drug monitoring and model-informed precision dosing are ready for selective clinical adoption in a subset of oral targeted therapies. Future prospective trials integrating pharmacometric tools with patient-centered outcomes are required to refine exposure targets and expand evidence-based implementation.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Torrent-Rodríguez A, Bastida C, Martín ECS, et al. Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation. Clin Pharmacokinet. 2026. PMID: 42283932. doi:10.1007/s40262-026-01660-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。